During the first year of this new agreement, Entelos will dedicate several teams of research engineers and life scientists to support specific projects using its PhysioLab platforms on behalf of J&J and its affiliates.
J&J is already using Entelos’ models to validate targets, select biomarkers, and optimize clinical trials for type 2 diabetes, obesity, and anemia.
From our earliest agreement signed in November 1999, J&JPRD and its affiliates recognized the value in accurately simulating human biology in silico (in a computer) to rapidly validate novel drug targets, discover biomarkers, and evaluate and develop new drugs, stated James Karis, president and CEO of Entelos.
